MedPath

Defibrillation Testing During Implantable Cardioverter Defibrillator (ICD) Replacement

Not Applicable
Completed
Conditions
Implantable Cardioverter-Defibrillators
Interventions
Diagnostic Test: Defibrillator threshold testing
Registration Number
NCT04206371
Lead Sponsor
CMC Ambroise Paré
Brief Summary

This study will evaluate safety and clinical outcomes of a systematic defibrillation threshold testing in patient with indication for defibrillator replacement.

Detailed Description

Implantable cardioverter defibrillators (ICD) are strongly recommended in patients with left ventricular systolic function ≤35% or selected patients with channelopathies and cardiomyopathies.

Defibrillation threshold testing (DFT) defines the minimal energy required to successfully terminate a ventricular arrhythmia by an ICD. It remains the gold standard to evaluate the electrical integrity of the device. However inherent complications of this procedure have been registered, such as refractory ventricular fibrillation, and the need for this practice during implant and/or replacement of ICD has recently been questioned.

If several studies have led to abandonment of the DFT during initial ICD implant, its interest during replacement is still controversial. Indeed, the leads essential for the device electrical integrity are older, more fragile, and the ICD replacement may damage it.

Device replacement is indicated when battery reaches the point of Elective Replacement Interval (ERI).

Patients over 18 years old with indication for replacement of defibrillator will be included. Patient's informations (comorbidities, medical history and events during hospitalization or follow-up) and device characteristics will be collected. Procedure will be realized under local or general anesthesia and prophylactic antibiotic will be administrated. Leads will be tested before and after the implantation of the new device. After connexion of the new implanted device to the leads a DFT will be performed. Protocol of DFT will be decided by the physician who will chose between induction of ventricular fibrillation or R-wave synchronized shock. Patients will be followed for 6 and 12 months from the date of defibrillator replacement.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
143
Inclusion Criteria
  • Patients with an ICD (VR or DR) or CRT-D undergoing generator replacement.
  • Consent for participation
  • Affiliation to the French social security system
Exclusion Criteria
  • Atrial Fibrillation without effective anti-coagulation treatments.
  • Severe Aortic valve stenosis
  • Stroke occurred in the previous month
  • Hemodynamic instability contraindicating the high energy shock
  • Contraindication for anesthesia
  • Pregnant or breastfeeding women
  • Communication difficulties or neuropsychiatric disorder
  • Patients under protection of the adults (guardianship, curators or safeguard of justice)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Defibrillation testing during ICD replacmentDefibrillator threshold testing-
Primary Outcome Measures
NameTimeMethod
Rate of defibrillator electrical integrity dysfunction during generator replacement.4 hours

Abnormal shock impedance value.

Secondary Outcome Measures
NameTimeMethod
Rate of lead malfunction12 months

abnormal impedance value

Trial Locations

Locations (7)

CHU de Toulouse-Hôpital Rangueil

🇫🇷

Toulouse, Occitanie, France

CHU de Caen

🇫🇷

Caen, Normandie, France

Hôpital Trousseau

🇫🇷

Chambray-lès-Tours, Centre-Val De Loire, France

Hôpital Privé du Confluent

🇫🇷

Nantes,, Pays De La Loire, France

Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu-CHU de Nancy-Hôpitaux de Brabois

🇫🇷

Vandœuvre-lès-Nancy, Grand Est, France

CMC Ambroise Paré

🇫🇷

Neuilly-sur-Seine, Ile-de-France, France

Centre Hospitalier Henri Duffaut

🇫🇷

Avignon, Provence-Alpes-Côte d'Azur, France

© Copyright 2025. All Rights Reserved by MedPath